Metformin use may be associated with decreased risk of prostate cancer
the ONA take:
According to a new study published in the journal European Urology, researchers have found that metformin use was associated with a decreased risk of prostate cancer diagnosis while other oral antihyperglycemics had no decreased risk.
For the nested case-control study, researchers identified 12,226 cases of prostate cancer among men residing in Northern Denmark between 1989 and 2011 from the Danish Cancer Registry and the Aarhus University Prescription Database.
They found that compared with never-users of metformin, metformin users had a decreased risk of prostate cancer diagnosis (adjusted OR = 0.84, 95% CI: 0.74 - 0.96). In addition, diabetics on no antihyperglycemics (adjusted OR = 0.98, 95% CI: 0.89 - 1.09) or on oral antihyperglycemics other than metformin (adjusted OR = 0.98, 95% CI: 0.86 - 1.10) did not have a decreased risk of prostate cancer. Insulin users also had a decreased risk of prostate cancer (adjusted OR = 0.77, 95% CI: 0.64 - 0.93).
Furthermore, among patients who had prostate-specific antigen (PSA) testing prior to 1 year before being indexed, metformin users had a decreased risk of prostate cancer versus nonusers (adjusted OR = 0.66, 95% CI: 0.51 - 0.86). In the same PSA-tested group, diabetics on no medication, other oral antihyperglycemics, or insulin did not have a significant reduced risk of the disease.
Metformin use associated with decreased risk of prostate cancer diagnosis.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|